Bristol Myers Squibb CELG-RI
NYSE CELG-RI
$0.12 +0.02 (+17.65%)
As of: Aug 21, 2026 · 2:40 PM EDT

Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Income towards Parent Company of $3.3 billion for Q2 2026, up 152.55% year-over-year from $1.3 billion in Q2 2025, and up 23.78% quarter-over-quarter from $2.7 billion in Q1 2026.

Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has reported Income towards Parent Company for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.

  • In Q2 2026, Income towards Parent Company rose 152.55% year-over-year to $3.3 billion; the TTM figure through Jun 2026 stood at $9.3 billion (up 83.1% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
  • Income towards Parent Company grew to $3.3 billion in Q2 2026 per CELG-RI's latest filing, from $2.7 billion in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $3.3 billion in Q2 2026 and bottomed at -$11.9 billion in Q1 2024.
  • Historically, Income towards Parent Company has averaged $1.0 billion across 5 years, with a median of $1.7 billion in 2023.
  • Annual changes were most pronounced in 2024 — Income towards Parent Company sank 625.28% — and 2025, when it soared 1328.95%.
  • Bristol Myers Squibb's Income towards Parent Company stood at $2.0 billion in 2022, then declined by 12.99% to $1.8 billion in 2023, then slumped by 95.69% to $76.0 million in 2024, then jumped by 1328.95% to $1.1 billion in 2025, then surged by 205.34% to $3.3 billion in 2026.
  • Business Quant data shows CELG-RI's Income towards Parent Company at $3.3 billion in Q2 2026, $2.7 billion in Q1 2026, and $1.1 billion in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Bristol Myers Squibb 224.21 Mn -10.84 Bn 9.25 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 3.32 Bn
Mar 31, 2026 2.68 Bn
Dec 31, 2025 1.09 Bn
Sep 30, 2025 2.20 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 2.46 Bn
Dec 31, 2024 76.00 Mn
Sep 30, 2024 1.22 Bn
Jun 30, 2024 1.68 Bn
Mar 31, 2024 -11.91 Bn
Dec 31, 2023 1.76 Bn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 2.08 Bn
Mar 31, 2023 2.27 Bn
Dec 31, 2022 2.03 Bn
Sep 30, 2022 1.61 Bn
Jun 30, 2022 1.43 Bn
Mar 31, 2022 1.28 Bn
Dec 31, 2021 2.37 Bn
Sep 30, 2021 1.55 Bn